PMID- 30861688
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1744-8417 (Electronic)
IS  - 1744-6651 (Linking)
VI  - 5
IP  - 3
DP  - 2010 May
TI  - Combination therapy for patients with Type 2 diabetes: repaglinide in combination 
      with metformin.
PG  - 331-342
LID - 10.1586/eem.10.17 [doi]
AB  - In patients with Type 2 diabetes mellitus (T2DM), adequate glycemic control is a 
      critical factor in reducing long-term micro- and macro-vascular complications. 
      Traditionally, the approach is to initiate monotherapy first, followed by 
      combination therapy that targets two main defects in T2DM. Repaglinide, a rapidly 
      acting insulin secretagog, stimulates insulin secretion via closure of 
      ATP-dependent potassium channels on the cell membrane of beta-cells. Repaglinide is 
      ideally used at mealtime to reduce postprandial glucose levels, thus lowering the 
      24-h blood glucose profile and improving HbA1c levels. Metformin is an insulin 
      sensitizer that effectively acts against insulin resistance, one of the 
      predominant metabolic defects in T2DM. A combination of repaglinide and metformin 
      is indicated as an adjunct to diet and exercise to improve glycemic control in 
      adults with T2DM. When monotherapy with oral antidiabetic agents fails, 
      combination therapy with repaglinide plus metformin has been demonstrated to be 
      safe and effective in the treatment of T2DM.
FAU - Moses, Robert G
AU  - Moses RG
AD  - a Clinical Trial and Research Unit, South Eastern Sydney and Illawarra Area 
      Health Service, PO Box W58, Wollongong West, NSW, 2500, Australia. 
      robert.moses@sesiahs.health.nsw.gov.au.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Endocrinol Metab
JT  - Expert review of endocrinology & metabolism
JID - 101278293
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - biguanides
OT  - combination therapy
OT  - hyperglycemia
OT  - insulin secretion
OT  - insulin sensitivity
OT  - meglitinide
OT  - metformin
OT  - repaglinide
EDAT- 2010/05/01 00:00
MHDA- 2010/05/01 00:01
CRDT- 2019/03/14 06:00
PHST- 2019/03/14 06:00 [entrez]
PHST- 2010/05/01 00:00 [pubmed]
PHST- 2010/05/01 00:01 [medline]
AID - 10.1586/eem.10.17 [doi]
PST - ppublish
SO  - Expert Rev Endocrinol Metab. 2010 May;5(3):331-342. doi: 10.1586/eem.10.17.